10X Genomics (TXG) has disclosed a new risk, in the Economy & Political Environment category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
10X Genomics faces the risk that it may not meet its publicly announced guidance or market expectations, given that its operating results are exposed to external factors such as macroeconomic conditions, competition, and regulatory change. Its limited operating history and rapid growth also hinder investors’ ability to reliably assess future prospects and the stability of its financial performance.
Volatility in the market price of its Class A common stock could impair 10X Genomics’ capacity to raise additional capital or execute strategic transactions on favorable terms. In addition, unknown or currently immaterial risks may emerge and interact with existing factors in unpredictable ways, potentially causing materially adverse impacts on its business, financial condition, and results of operations.
Overall, Wall Street has a Moderate Buy consensus rating on TXG stock based on 3 Buys and 8 Holds.
To learn more about 10X Genomics’ risk factors, click here.